博瑞醫藥(688166.SH):擬出資1000萬元參與對保易製藥增資
格隆匯12月29日丨博瑞醫藥(688166.SH)公佈,為提升製藥技術綜合能力,完善“起始物料→高難度中間體→特色原料藥→製劑”的全產業鏈佈局,公司擬簽署《有關江蘇保易製藥有限公司之增資協議》,參與對保易製藥增資。保易製藥本輪增資共增加註冊資本1500萬元,其中公司擬以自有資金1000萬元認購保易製藥人民幣116.6667萬元的新增註冊資本。
增資款中,人民幣116.6667萬元作為標的公司新增註冊資本,人民幣883.3333萬元作為溢價進入標的公司資本公積金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.